Global Manufacturing Excellence Across Quality, Efficiency, And Cost Of Goods Sold

Ensure Successful Viral Clearance

Deciphering The Complexity Of Therapeutic Biologics

Flexible Therapeutic Development: Balancing Speed, Cost, and Process

Accelerating Vector Construction-To-IND: Achieving A 9-Month Timeline Through Integrated Cell Line Development

Solvias Capabilities Update March 2026: Analytical Services

Catalent Capabilities Update March 2026: Analytical Services

Minaris Advanced Therapies Capabilities Update March 2026: Cell & Gene Therapy

Lonza Capabilities Update March 2026: Cell & Gene Therapy

Landmark Bio Capabilities Update March 2026: Cell & Gene Therapy

Comprehensive Cell Solutions Capabilities Update March 2026: Cell & Gene Therapy

Enhanced Biotherapeutic Protein Expression Using Advanced Vector Systems

Eliminating Barriers To In Vivo And Ex Vivo CAR-T Delivery

Minimizing Drug Product Loss In Manufacturing

Lonza Capabilities Update March 2026: Cell & Gene Therapy

Enhanced Biotherapeutic Protein Expression Using Advanced Vector Systems

Fostering Effective Sponsor–CDMO Collaboration (Trust vs. Oversight)

Ensuring Quality And Regulatory Compliance In Outsourced Manufacturing

Avoiding And Mitigating Delays In Outsourced Projects

Key Elements Of Effective Tech Transfer Management

Selecting The Right CDMO Partner For Small Molecule Development

Establishing Realistic Development Timelines With A CDMO

Extrusion-Based ASD Scale-Up: Performance Through Process Understanding

Small Molecule Outsourcing: Getting Timelines, Tech Transfer, And Analytics Right

Sustainable Manufacturing Through Automation, Flow Chemistry, And Biocataysis

My Journey at Asymchem

R&D Excellence at Asymchem's UK Facility

Accelerating Small Molecule Development With Cutting-Edge Technology

Quick View Of Asymchem's New OEB5 Facility

Quotient Sciences Capabilities Update March 2026: Small Molecule Drug Product

Pfizer CentreOne Capabilities Update March 2026: Small Molecule Drug Product

PCI Pharma Services Capabilities Update March 2026: Small Molecule Drug Product

Mikart Capabilities Update March 2026: Small Molecule Drug Product

Asymchem Capabilities Update March 2026: Small Molecule Drug Product

NuTekBio Facilities Tour

WuXia293Stable: Express What CHO Can't

Global Manufacturing Excellence Across Quality, Efficiency, And Cost Of Goods Sold

Ensure Successful Viral Clearance

Deciphering The Complexity Of Therapeutic Biologics

Quotient Sciences Capabilities Update March 2026: Small Molecule Drug Product

Pfizer CentreOne Capabilities Update March 2026: Small Molecule Drug Product

PCI Pharma Services Capabilities Update March 2026: Small Molecule Drug Product

Mikart Capabilities Update March 2026: Small Molecule Drug Product

Asymchem Capabilities Update March 2026: Small Molecule Drug Product

SK Pharmteco Capabilities Update March 2026: Small Molecule Drug Substance

Novartis Capabilities Update March 2026: Small Molecule Drug Substance

Ropack Pharma Solutions Capacity Update October 2025: Small Molecule

Pfizer CentreOne Oral Solids Capacity Update October 2025: Small Molecule

Lonza Capacity Update October 2025: Small Molecule

Douglas CDMO Capacity Update October 2025: Small Molecule

Alcami Capacity Update October 2025: Small Molecule

Upperton Pharma Solutions Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form

Quotient Sciences Capacity Update July 2025

PCI Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form

Your Boutique CDMO Partner Of Choice

Comprehensive CDMO Services From Clinical To Commercial Supply

MilliporeSigma Capacity Update July 2025: Small Molecule Drug Substance/API

Amorphous Solid Dispersions: Pre-Clinical To Commercial Capabilities

Your Integrated Drug Substance Partner

How Can CMC Keep Up With The Rush To The Clinic?

Outsourcing Not Plug-And-Play

You Need A Gap Analysis Before Outsourcing

Speeding Up The Regulatory Side Of Outsourcing

Consultants Know: Emerging Biotechs Have Outsourcing "Disconnects"

A New Acronym – CBMC? Put "Biology" In CMC? Our Panelists Think Not.

When Outsourcing, Get The Right Professionals On Your Internal Team

Speed To Clinic, Cost To Get There, And FDA Expectations

"Relentless Transparency" Needed Between CDMO And Biotech Customer

How Much Can You Actually Rely On Your CDMO?

How Much Do You Need To Pay Your CDMOs … And When?

Can't Afford A Head Of Clinical And CMC? Think Again

Investing In Early-Stage Oncology With Yosemite's Dan McHugh

Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash

Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.

Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D.

Making Biologics Orally Available With Vivtex's Thomas von Erlach, Ph.D.

An Anthropological Lens On Leadership In Life Sciences With Bunka's Monika Sumra, Ph.D.

Company Turnarounds And AI For Infectious Diseases With Seek Labs' Jared Bauer

Bringing Curative Cell Therapies To Market with Kite Pharma's Cindy Perettie

BoB@JPM: Brian Hilberdink, Boehringer Ingelheim

BoB@JPM: Ron Cooper, enGene

BoB@JPM: Marc Salzberg, M.D., Airway Therapeutics

A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith

Life Science Connect Editors' Roundtable: Wrapping Up 2025 And Looking Ahead

Building Cell Therapy Companies With Kenai Therapeutics' Nick Manusos

Modernizing Clinical Trial Operations With Merck's Jennifer Sheller

Transforming Chronic Kidney Disease With ProKidney's Bruce Culleton, M.D.

Engineering B Cells With Immusoft's Sean Ainsworth

Building A Cancer Pipeline In A Molecule With Actuate Therapeutics' Dan Schmitt

Biotech Collaboration Strategy With IGI's Cyril Konto, M.D.

Biotech Funding And IPO Temperature Check With CREATE Medicine's Allan Shaw

Funding Tips And Moving From R&D To Commercial With Madrigal Pharmaceuticals' Mardi Dier

Emerging From Stealth With Vima Therapeutics' Bernard Ravina, M.D.

BoB in South Florida: Rich Daly, Catalyst Pharmaceuticals

BoB In South Florida: Anthony Japour, M.D., iTolerance

BoB In South Florida: Daniel Teper, NAYA Therapeutics

BoB In South Florida: Raquel Cabo, Miami Biotech Collective

The Business Case For Health Economics And Outcomes Research With ISPOR's Rob Abbott

Cannabinoid And Psychedelic Combinations With Incannex Healthcare's Joel Latham

Dye Drug Conjugates For Cancer With Lahjavida's Lyle Small

Investing In The Biostack With Modi Ventures' Sahir Ali, Ph.D.

Improving Cardiovascular Outcomes With Immediate Therapeutics' Atul Deshpande, Ph.D.

Building A Biotech Incubator And Accelerator With Swiss Rockets Founder And CEO Vladimir Cmiljanovic, Ph.D.

Biotech Product Partnership with Coya Therapeutics' Arun Swaminathan, Ph.D. and Dr. Reddy's Milan Kalawadia

How To Hire And Build A Winning Executive Team With Occam Global's Bill Holodnak

The Generalist Biotech CEO With Seekyo's Oury Chetboun

Innovating On The Frontier Of Radiopharmaceuticals With RadioMedix's Ebrahim Delpassand, M.D.

Building An Efficient Biopharma With South Rampart Pharma's Hernan Bazan, M.D.

The Business And Science Of Obesity With Roger Cone, Ph.D., Founder Of Courage Therapeutics

BoB Live At BIO: Amber Salzman, Ph.D., Epicrispr Biotechnologies

How To Be A Policy Advocate For Biotech With NewYorkBIO's Jennifer Hawks Bland

FDA Trials And Tribulations With Connect Biopharma's Barry Quart

Proactive Procurement Strategies For Biotech With Tom Wells

The Discovery Of Microbes And Implications For Public Health Today, With Science Writer Thomas Levenson

Psychedelics For Mental Health Disorders With atai's Srinivas Rao, M.D., Ph.D.

Biotech Angel Investing With Yaniv Sneor

Leading A tRNA Startup With Alltrna's Michelle Werner

Executing A Product Pivot With Vir's Mark Eisner, MD

Commercializing RNAi Therapies With Alnylam's Tolga Tanguler

Big Pharma Insights For Building Biotech Startups With Uniquity Bio's Brian Lortie

The Implications Of China's Growing Biotech Industry With Allan Shaw

Regulatory Flexibility in CGT: Key Shifts and Implications with Monika Swietlicka

Scaling CRISPR For Rare Disease With Aurora Therapeutics' Dr. Edward Kaye

Simplifying Friction in Cell Therapy Clinical Trials with Dr. Panteli Theocharous

Inside a Breakthrough HER2 Immunotherapy for PMO with OS Therapies' Paul Romness

Building Safer CRISPR Medicines for CVD with Scribe Therapeutics' Benjamin Oakes

Advancing Off-The-Shelf CRISPR CAR-T Therapies Into The Community Setting With Caribou Biosciences' Rachel Haurwitz

The Editors' Roundtable: A 2025 Retrospective of the Life Sciences Industry

Developing Itvisma for Broad-Range Treatment of SMA with Novartis' Dr. Norman Putzki

Turning the Tumor Microenvironment Against Cancer with MGB's Alexander Cryer, Ph.D.

Building Patient-Driven Culture and Leadership Resilience in CGT with Paul Perreault

Treating Inherited Retinal Disorders with Ocugen's Dr. Arun Upadhyay

Advancing Hematology and Cell Therapy Innovation with AstraZeneca's Aliya Omer

Advancing Allogeneic Cell Therapy for SCI and Blindness with Lineage's Brian Culley

How AI and ML Drive iPSC Quality with Aspen Neuroscience's Thorsten Gorba, Ph.D.

Inside Sanofi's Genomic Medicine Vision with Mike Quigley, Ph.D.

Engineering Off-The-Shelf Cell Therapies For Cancer And Autoimmune Disease With Ernexa Therapeutics' Sanjeev Luther

What Changes to FDA and CBER Mean for the Future of CGT with Daniela Drago

Inside CRISPR-GPT With Yuanhao Qu

Barriers, Breakthroughs, and Building Access in Pediatric CGTs with Bambi Grilley, Ph.D.

Defining Product Roles and Navigating FDA Approval with Monika Swietlicka

Advancing Gene Therapy for FTD with Passage Bio's Dr. Will Chou

FDA Fridays: Advancing Communication and Consistency in CGT Regulation with Kaye Spratt

Navigating The Journey To Safer Stem Cell Therapies With Orca Bio's Nate Fernhoff

Rethinking Large Animal Models in Gene Therapy with Novartis' Ralf Schmid, Ph.D.

Gene Therapy for Inherited Retinal Diseases with Opus Genetics' Dr. George Magrath

Extracellular Vesicle Breakthroughs with Aegle Therapeutics' Dr. Gloria Matthews

Bridging Development and Regulation in CGT with Halloran Consulting Group's Monika Swietlicka

Harnessing AI and Synthetic Biology for Cell Therapies with Generate:Biomedicines' Dr. Alex Snyder

Redefining Heart Failure Treatment with Precision Autologous Cell Therapy with BioCardia's Peter Altman, Ph.D.

Rethinking CGT Biotech Growth & Investment with Audrey Greenberg

Advancing Retinal Gene Therapy with Atsena Therapeutics' Dr. Kenji Fujita

Harnessing the Power of Cord Blood Tregs with Cellenkos' Dr. Simrit Parmar

CGT Manufacturing: Distributed & Digital with Deloitte Consulting's Omkar Kawalekar, Ph.D.

Inside Gene Therapies for Cardiac Care with Tenaya Therapeutics' Faraz Ali

The Future of Adenovector-Based Therapies with Precigen's Helen Sabzevari, Ph.D.

The Future of NK Cell Therapy for Autoimmune Disease with Artiva Biotherapeutics' Christopher Horan

Lessons in Automation with Roswell Park Comprehensive Cancer Center's Christopher Choi, Ph.D.

Can Gene Therapy Be The Solution For CHF With AskBio's Dr. Lothar Roessig

Inside A Dopamine-Restoring Cell Therapy For PD With BlueRock Therapeutics' Dr. Amit Rakhit

Globalization's Impact on Patient Access with ARM's COO, Rita Johnson-Greene

Improving TCR T-Cell Persistence and Efficacy with Adaptimmune's Dennis Williams

Live from ARM's Meeting on the Mesa with Kiji Therapeutics' Dr. Miguel Forte

Pioneering Next-Gen TCR Therapies In Solid Tumors With Neogene Therapeutics' Carsten Linnemann, Ph.D.

Optogenetics for Vision Restoration with Ray Therapeutics' Paul Bresge

Identifying Drug Development Opportunities For DMD With CureDuchenne

Tackling 'The Delivery Problem' Of Gene Editing-Based Medicines